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We evaluate the performance of the TBcID assay in a panel of 100 acid-fast bacilli cultures. Sixty-four isolates were TBcID
positive for Mycobacterium tuberculosis complex (MTBC), whereas 36 gave negative results. These included 28 nontuberculous
mycobacteria, one nonmycobacterial isolate, oneM. tuberculosis, and sixM. bovis BCG strains. This corresponds to a sensitivity of
90.14%, specificity of 100%, and positive and negative predictive values of 100% and 80.55%, respectively. The test is rapid, easy to
perform and interpret, and does not require sample preparation or instrumentation. However, a negative result does not exclude
the presence of a strain belonging to MTBC, especially when mutations in mpb64 gene are present or someM. bovis BCG strains
are isolated.The TBcID showed potential to assist in the identification of MTBC when the implementation and usage of molecular
methods are often not possible, principally in resource-limited countries.
1. Introduction
The genus Mycobacterium comprises over 150 species of
which more than 30 can cause disease in livestock, wildlife,
and humans [1, 2]. Members of the Mycobacterium tubercu-
losis complex are the etiologic agents of tuberculosis and the
responsible for about 8.6 million of new tuberculosis cases
and 1.3 million deaths in 2012 [3]. Nontuberculous mycobac-
teria are a cause of opportunistic infections and are frequently
encountered in clinical samples [1]. In some cases, clinical
presentation of pulmonary disease caused by nontuberculous
mycobacteria is very similar to that of tuberculosis [4].There-
fore, rapid diagnosis of patients with active tuberculosis is of
major importance for the control of the disease demanding
for reliable, easy to perform instrument-free identification
assays, especially for low-income countries. Fast and accurate
differentiation between M. tuberculosis complex and nontu-
berculous mycobacteria is essential, as it enables the imple-
mentation of appropriate measures to prevent the spread of
the infection, allows the implementation of appropriate ther-
apy, and prevents inappropriate drug susceptibility testing
without species identification. Moreover, the differentiation
of nontuberculous mycobacteria is important, since some of
these species are resistant to most of the first line antibiotics
used in tuberculosis therapy [4].
The conventional methods employed for the diagnosis of
mycobacterial diseases rely on acid fast staining, culture, and
phenotypic characterization. The development and imple-
mentation of liquid culture media allowed the reduction of
the time for detection of positive cultures. From these, the
BACTEC MGIT 960 is the most sensitive for recovery of
mycobacteria from clinical samples [5]. After the positivity
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of a culture, the verification of the presence or absence of
acid fast bacilli in the culture can be achieved by means of
microscopy. Nevertheless, it does not distinguish betweenM.
tuberculosis and nontuberculous mycobacteria. Usually, most
laboratories in resource-limited settings use the labor inten-
sive standard biochemical tests to identify M. tuberculosis
complex, which requires subculture of mycobacteria on solid
media and delay the result by several weeks. This process
increases the turnaround time for reporting positive results.
Nucleic acid probe and amplification based methods have
been used for the identification ofmycobacteria fromcultures
or directly from clinical samples thus reducing the time for
diagnosis [6, 7]. However, since molecular methods do not
distinguish between live and death bacteria, culture confir-
mation ismandatory.Moreover, these techniques require spe-
cific equipment, expensive reagents requiring refrigeration,
and highly trained personnel.
Lateral flow assays, also called immunochromatographic
assays, have been developed for the discrimination between
M. tuberculosis complex and nontuberculous mycobacteria.
These include the SD Bioline Ag MPT64 Rapid assay (Stan-
dard Diagnostics, Kyonggi-do, Korea), Capilia TB (TAUNS,
Numazu, Japan), and theMGIT TBc Identification Test (Bec-
ton Dickinson Diagnostic Instrument Systems, Sparks, MD).
These sandwich-type assays use a monoclonal antibody to
detect the MPB64 protein (Rv1980c; also termed as MPT64),
which is specifically secreted during growth by theM. tuber-
culosis complex [8]. The MPB64 is a 24 kDa protein, highly
specific for theM. tuberculosis complex, except some variants
of Mycobacterium bovis BCG [9, 10]. In this study we inves-
tigated the performance of the BD MGIT TBc identification
test for the discrimination between M. tuberculosis complex
and nontuberculous mycobacteria grown in both liquid and
solid medium for the routine discrimination of M. tubercu-
losis complex in our setting and the reliability of the MPB64
protein forM. tuberculosis complex identification. This assay
is intended to be used as a preliminary screening identifica-
tion test when the hospital laboratories only performacid-fast
smear staining and culture and send their isolates to interme-
diate or reference laboratories for molecular identification at
the species level and susceptibility testing of M. tuberculosis.
This study was carried out as part of the training pro-
grams in TB laboratory diagnosis for Mozambique and other
Portuguese speaking countries, created and implemented to
assess the usefulness of this assays for routine identification of
M. tuberculosis in the network of hospital mycobacteriology
laboratories in these countries as well as in Portugal.
2. Methods
2.1. Mycobacterial Strains and Culture. A total of 100 culture
isolates received from seven hospitals of the Lisbon Health
Region during the training period of three months were
included in this study. These comprised 71 strains of the M.
tuberculosis complex, 28 nontuberculous mycobacteria, and
one acid-fast bacilli other than mycobacteria (Table 1). M.
tuberculosis H37Rv and M. bovis BCG Pasteur strain were
used as controls. As an intermediate level laboratory in the
network of hospital mycobacteriology laboratories in Lisbon,
Table 1: Identification of M. tuberculosis complex and differentia-
tion from nontuberculous mycobacteria by the TBcID.
Mycobacterial species (𝑛) TBcID
Positive Negative
M. tuberculosis complex (71) 64 7
Nontuberculous mycobacteria (28) 0 28
AFB high G+C bacteria (1) 0 1
AFB: acid-fast bacilli.
the Mycobacteriology Laboratory of the IHMT/UNL only
receives acid-fast smear positive cultures for molecular iden-
tification and drug susceptibility testing from the hospital
laboratories. All isolates were processed for Ziehl-Neelsen
staining and inoculated into MGIT culture tubes and
Lowenstein-Jensen slants. Samples were digested and decon-
taminated, by the standard sodium hydroxide-N-acetyl-L-
cysteine (NaLC-NaOH) method [11]. Once a positive signal
was given by the BACTEC system, a Ziehl-Neelsen staining
was performed and the presence or absence of serpentine
cordingmorphologywas observed.Only acid-fast bacilli pos-
itive cultures were included in the study. Presence of contami-
nationwas evaluated by inoculation of the cultures into blood
agar plates and Ziehl-Neelsen staining.
2.2. TBcID Assay. TheTBcID assay (BectonDickinsonDiag-
nostic Instrument Systems, Sparks, MD) consists of a nitro-
cellulose membrane on a test device with immobilized anti-
MPB64 mouse monoclonal antibodies conjugated with gold
colloidal for the detection of the MPB64 protein. In the pres-
ence of a sample, the antibody-colloidal gold conjugate binds
to the MPB64 antigen and flows laterally through the mem-
brane until the reaction zone. Here, the complex will be cap-
tured by a second antibody specific forMPB64. If theMPB64
protein is present, a purple band will be developed. Each
TBcID device was inoculated with 100𝜇L of a positive MGIT
culture. All cultures were tested with growth units above 100
(GU ≥ 100) and between day 1 and day 5 after positivity
within the MGIT system. Selected M. tuberculosis isolates
from the same collection were evaluated with cultures grown
in Lowenstein-Jensen. For that, one loopful of colonies was
suspended in 200𝜇L of extraction buffer (phosphate buffer
with 0.05% Tween 20 and 0.02% sodium azide) and 100𝜇L of
the suspension used in the assay.The results were interpreted
15min after application of the sample. A positive result was
indicated by the development of two purple bands, one in the
control zone (C) and another in the test zone (T). The pres-
ence of the control band alone indicates a negative result.
2.3. Confirmatory Identification Tests. All the results obtained
with TBcID were compared with Accuprobe MTBC culture
identification test (GenProbe Inc., San Diego, CA) as the
“gold standard” for the identification of the M. tuberculosis
complex. Briefly, 1mL of the each culture was centrifuged
during 10min at 13000 rpm and the pellet was used for
hybridization according to the instructions of the manu-
facturer. The isolates that were negative for M. tuberculosis
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Table 2: Comparison of the results obtained by the TBcID and the Accuprobe assay.
Mycobacterial species (𝑛) TBcID Accuprobe
Positive (𝑛) Negative (𝑛) Positive (𝑛) Negative (𝑛)
M. tuberculosis complex
M. tuberculosis (64) 63 1 64 0
M. bovis BCG (6) 0 6 6 0
M. africanum (1) 1 0 1 0
Nontuberculous mycobacteria
M. abscessus (2) 0 2 0 2
M. avium (4) 0 4 0 4
M. intracellulare (5) 0 5 0 5
M. chelonae (2) 0 2 0 2
M. fortuitum (1) 0 1 0 1
M. genavense (2) 0 2 0 2
M. gordonae (4) 0 4 0 4
M. kansasii (1) 0 1 0 1
M. marinum (2) 0 2 0 2
M. peregrinum (1) 0 1 0 1
M. scrofulaceum (1) 0 1 0 1
M. szulgai (1) 0 1 0 1
M. xenopi (1) 0 1 0 1
M. ulcerans (1) 0 1 0 1
Nonmycobacteria
AFB high G+C bacteria (1) 0 1 0 1
BCG: Bacillus Calmette-Guérin. AFB: acid-fast bacilli.
complex by Accuprobe were identified using the Genotype
CM/AS (Hain, Nehren, Germany) according to manufac-
turer’s instructions. Total genomic DNA for the Genotype
CM/AS assays was extracted from the cultures using the
QIAampDNAmini kit (QIAGEN,GmbH,Hilden, Germany)
according to the manufacturer’s instructions.
2.4. Assessment of Discordant Results. The isolates that were
positive forM. tuberculosis complex withAccuprobe but neg-
ative with the TBcID were tested using the Genotype MTBC
(Hain) assay, according tomanufacturer’s instructions.Muta-
tions in the mpb64 gene of M. tuberculosis were analyzed by
PCR amplification and DNA sequencing using the primers
mpb64-F30 andmpb64-R433,mpb64-F404 andmpb64-R891,
described elsewhere [12]. The reaction mixtures were pre-
pared for a total reaction volume of 50 𝜇L consisting of 1x
Taq buffer (Fermentas, Ontario, Canada), 1.5mM MgCl
2
,
200mM of each dNTP, 10 pmol of each primer, 1.5 U Taq
DNA Polymerase (Fermentas), and 5 𝜇L of chromosomal
DNA.The PCR reactions were performed with the following
amplification profile: initial denaturation at 94∘C for 5min,
followed by denaturation at 94∘C for 1min, annealing at 62∘C
for 1min, and extension at 72∘C for 1min during 40 cycles.
Thefinal extension occurred at 72∘C for 10min. PCRproducts
were sequenced with an ABI Prism 3130 capillary sequencer
(Applied Biosystems, Foster City, CA) and the BigDye termi-
nator kit (ABI Prism).
2.5. Performance Analysis. The sensitivity, specificity, and
positive and negative predictive values of the TBcID assay
were determined using the results of the Accuprobe MTBC
culture identification test as the gold standard.
3. Results
The results obtained are summarized in Tables 1 and 2. Of the
100mycobacterial cultures tested, 64were correctly identified
asM. tuberculosis complex by the TBcID. The assay failed to
detect one M. tuberculosis isolate that carried a mutation in
the mpt64 gene and allM. bovis BCG tested (𝑛 = 6). We did
not observe cross-reaction with any of the 28 nontuberculous
mycobacteria and the one nonmycobacterial acid-fast bacilli
culture tested.These correspond, in this study, to a sensitivity
of 90.14%, specificity of 100%, positive predictive value of
100%, and negative predictive value of 80.55% of the TBcID
assay for the identification of theM. tuberculosis complex.
From the seven false negatives yielded by TBcID one
corresponded to an M. tuberculosis strain as determined by
Accuprobe. To evaluate if the negative result was due to a
reduced amount of secretedMPB64 protein necessary for the
detection, this isolate was subcultured and the test was
repeated. The result was again negative. After this, the entire
mpb64 gene was sequenced and an insertion of two bases
(CG) at position 335 of the genewas detected.This frame shift
resulted in the generation of a premature stop codon at amino
acid position 167, truncating the protein. The remaining
six isolates were identified asM. bovis BCG by the Genotype
MTBC assay and these isolates were later on found to belong
to one child BCGitis and from patients that are being mon-
itored for bladder cancer immunotherapy [13]. Testing by
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Figure 1: Identification of M. tuberculosis complex isolates by
the MGIT TBc ID assay from (a) positive MGIT culture and
(b) Lowenstein-Jensen slants. In the Figure it is shown the result
of the TBcID for the same isolate when grown in different culture
media. The positive result is indicated by the development of two
purple bands, one in the control zone (C) and another in the test
zone (T).
polymerase chain reaction with the four primers confirmed
that thempb64 gene is absent in these strains.
The manufacturer’s instructions of the TBcID system
recommend its use with isolates grown in liquid media only.
Nevertheless, we decided to test the capability of the test to
detect MPB64 protein in strains grown on solid media. For
that we selected 25 M. tuberculosis isolates from the panel
of isolates grown in liquid media previously evaluated. The
test demonstrates a good performance for detection of M.
tuberculosis complex from solid cultures as all isolates were
correctly identified as M. tuberculosis complex (Figure 1 and
Table 3).
4. Discussion
In this work, the performance of the BD MGIT TBc identifi-
cation test was evaluated for the identification of M. tuber-
culosis complex and differentiation from nontuberculous
mycobacteria. We did not detect false positive results. How-
ever, the TBcID assay yielded seven false negative results.The
assay demonstrates 100% of specificity which is similar to that
published in other studies [14–16]. Nevertheless, the sensitiv-
ity was found to be 90.14%, which is lower than that reported
by other authors (between 95.2 and 100%) [14–16]. This fact
can be explained by the false negative results obtained.
The occurrence of false negatives can be due to the
absence of the MPB64 protein or mutations in the coding
gene, mpb64. Several studies have reported false negatives
results for several BCG strains [14, 17, 18]. Among the M.
bovisBCG variants, some of themdo not produce theMPB64
Table 3: Results of the TBcID for a subset of 25 M. tuberculosis
complex strains using different culture media.



























Total (25) 25 25
(+) positive result.
antigen, whereas others are good secretors of this antigen
[19]. This difference is due to the deletion of the mpb64 gene
together with the RD2 [20]. One of the strains included in
this study was the BCG Pasteur, already described as a non-
producer of theMPB64 antigen [21, 22]. In Portugal, BCG SSI
(strain 1331) is used for vaccination and BCG Medac is used
for treatment of noninvasive urothelial bladder carcinoma
and thus we assume that we have found both strains in our
study, since one strain came from a child who developed
osteomyelitis after BCG vaccination and five strains were iso-
lated from patients undergoing cancer therapy [13]. Another
possible explanation for the occurrence of negative results is
the presence of mutations within the mpb64 gene. Several
mutations are reported in the literature for this gene [12, 15, 16,
18, 22–24]. In this study, we detected a GC insertion at nt 335,
which resulted in a truncated protein and a TBcID negative
result for this M. tuberculosis strain. As far as we know, this
mutation has not been previously reported. Further, due to
the existence of some strains of M. tuberculosis with delayed
MPB64 secretion some cultures might lead to erroneous
reporting of negative results. Vadwai et al. [25] propose that a
culture must be tested with GU ≥ 300 to avoid false negative
results. In our study, we did not detect false negative results
using as cutoff MGIT cultures with GU ≥ 100.
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Differentiating M. tuberculosis complex from nontuber-
culous mycobacteria as soon as possible is important, mainly
in situations in which nontuberculous mycobacteria strains
represent a considerable portion of mycobacteria isolated
[26]. The nontuberculous mycobacteria and one acid fast
bacilli other than mycobacteria tested in this study correctly
provided true negative results. Serpentine cord morphology
can be used for rapid presumptive identification ofM. tuber-
culosis in liquid culture and as a guide for the selection of
auxiliary tests. Using this feature, we were able to improve
the sensitivity of the test since the combination of the ser-
pentine cordingmorphologywith the TBcID comparingwith
AccuProbe assay as the gold standard corresponds to a sensi-
tivity and specificity of 100% and identical positive and neg-
ative predictive values (data not shown). Similar results were
reported by others [27]. The capacity of the TBcID was also
evaluated for the identification of a subset of 25M. tuberculo-
sis strains grown on solid media, and all the 25 isolates were
correctly identified asM. tuberculosis complex.
The main advantages of the test are the cost and rapidity.
However, it has some disadvantages. The method (i) cannot
be applied directly to clinical samples; (ii) does not allow the
identification at species level; and (iii) requires further con-
firmatory tests for identification at species level. The MPB64
protein is the target of the test but it is also its weak point.
All negative results suspected for M. tuberculosis complex
had to be tested with other methodologies. Noteworthy, the
isolation ofM. bovis from human samples is uncommon, but
sporadically, BCG strains are isolated from patients receiving
BCG immunotherapy.The fact that all of our BCG strains are
negative for MPTB64 can be useful to assist in the detection
of BCG strains since it can be used as a screening tool in com-
bination with molecular methods. Our results show that the
TBcID is not an alternative to the Accuprobe system, at least
in our work algorithm, due to the false negative results pre-
sented and this also precludes its use for confirmatory labora-
tory diagnosis of tuberculosis infections. Another limitation
is related to the safetymeasures.The test necessitates biosafety
level 3 conditions to be applied as it involves a considerable
bacterial inoculum. When these conditions are not present,
the test must be performed with heat-inactivated cultures
[14].
The BD MGIT TBc identification test showed potential
to assist in the identification of M. tuberculosis complex and
differentiation from nontuberculous mycobacteria when the
implementation and usage of molecular methods are often
not possible, principally in resource-limited countries. The
test is simple, rapid, easy to perform and interpret, and
does not require sample preparation or instrumentation. In
Mozambique, in 2012 the TB Reference Laboratories from
Maputo and Beira have introduced the immunochromato-
graphic assay, a very important step in a country for which
very limited information regarding the occurrence of nontu-
berculous mycobacteria is available [28]. In 2012, among all
positive cultures, 20.5% were from single or mixed infection
from nontuberculous mycobacteria, a strong evidence of
the high prevalence of nontuberculous mycobacteria in this
country that are often misidentified and might be considered
as multidrug resistant tuberculosis.
This study demonstrated the usefulness of the immun-
ochromatographic assays for routine identification of M.
tuberculosis in a network of mycobacteriology laboratories as
preliminary screening identification test of cultures to be sent
to the intermediate or reference laboratory as part of the net-
work of TB laboratories of the national tuberculosis control
programs.
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